Kezar Life Sciences - KZR Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KZR shares.
View KZR analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month price objectives for Kezar Life Sciences' stock. Their KZR share price forecasts range from $17.00 to $22.00. On average, they anticipate the company's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.

Kezar Life Sciences' stock was trading at $16.72 at the beginning of 2022. Since then, KZR shares have decreased by 41.8% and is now trading at $9.73.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our KZR earnings forecast.

Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (4.59%), Deutsche Bank AG (0.50%), Connor Clark & Lunn Investment Management Ltd. (0.40%), Russell Investments Group Ltd. (0.19%), Simplex Trading LLC (0.00%) and Swiss National Bank (0.17%). Insiders that own company stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Michael Kauffman, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends.

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KZR stock can currently be purchased for approximately $9.73.

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $587.89 million. The company earns $-54,630,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.